Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand
²10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: November 21, 2022; Published: December 01, 2022

Systemic sclerosis (SSc; aka scleroderma), an autoimmune disease with hypothesized etiology of non-infectious, infectious, and genetic origins [1]. SSc is rarely associated with renal cell carcinoma (RCC-being diagnosed around 338,000 new cases annually worldwide [2]), whereas it may be associated with most commonly increased risk of lung (most common site [Figure 1-4]; [3-5], around 45-76% of metastatic RCC [5-7]), breast, and skin cancers [1] and metastases (being diagnosed around 20-30% of RCC patients at the time of diagnosis of RCC [3-5]) [8], including hematologic malignancies [9].

References

1. Patel HS., et al. “Scleroderma associated with renal cell carcinoma: a case report and literature review”. Journal of Scleroderma and Related Disorders3 (2021): 316-319.
2. Ferlay J., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. International Journal of Cancer 136 (2015): E359-E386.
3. Motzer RJ., et al. “Renal cell carcinoma”. The New England Journal of Medicine 335 (1996): 865-875.
4. Weiss L., et al. “Metastatic patterns of renal carcinoma: an analysis of 687 necropsies”. Journal of Cancer Research and Clinical Oncology 114 (1988): 605-612.
5. Bianchi M., et al. “Distribution of metastatic sites in renal cell carcinoma: a population-based analysis”. Annals of Oncology 23 (2012): 973-980.
6. Bukowski RM. “Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2”. Cancer 80 (1997): 1198-1220.
7. Saitoh H. “Distant metastasis of renal adenocarcinoma”. Cancer 48 (1981): 1487-1491.
8. Crosnier C., et al. “Scleroderma renal crisis and cancer”. QJM: An International Journal of Medicine4 (2018): 261-262.
9. Zeineddine N., et al. “Systemic sclerosis and malignancy: a review of current data”. Journal of Clinical Medicine Research 9 (2016): 625-632.
10. Cohen HT and McGovern FJ. “Renal cell carcinoma”. The New England Journal of Medicine 353 (2005): 2477-2490.
11. Kovacs G., et al. “The Heidelberg classification of renal cell tumors”. Journal of Pathology 183 (1997): 131-133.
12. Beck SD., et al. “Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma”. Annals of Surgical Oncology 11 (2004): 71-77.
13. Störkel S., et al. “Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)”. Cancer 80 (1997): 987-989.
14. Braman SS and Whitcomb ME. “Endobronchial metastasis”. Archives of Internal Medicine 135 (1975): 543-547.
15. Noy S., et al. “Endobronchial metastasis of renal cell carcinoma”. Journal of Surgical Oncology 31 (1986): 268-270.
16. Motzer RJ., et al. “Kidney cancer, version 3.2015”. Journal of the National Comprehensive Cancer Network 13 (2015): 151-159.
17. Klapper JA., et al. “High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006”. Cancer 113 (2008): 293-301.
18. Allard CB., et al. “Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States”. Urology and Oncology 33 (2015): 496.e11-496.e16.
19. Cerfolio RJ., et al. “Pulmonary resection of metastatic renal cell carcinoma”. Annals of Thoracic Surgery 57 (1994): 339-344.
20. Hofmann HS., et al. “Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma”. European Urology 48 (2005): 77-81; discussion, 81-82.
21. De Bae‛re T., et al. “Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1,037 metastases”. Annals of Oncology 26 (2015): 987-991.
22. Altoos B., et al. “Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT)”. Radiation Oncology Journal 10 (2015): 218.
23. Wersall PJ., et al. “Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma”. Radiotherapy Oncology 77 (2005): 88-95.

Citation

Citation: Attapon Cheepsattayakorn., et al. “Scleroderma-Induced Renal Cell Carcinoma with Lung Metastasis". Acta Scientific Pharmaceutical Sciences 7.1 (2023): 01-04.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.